Clinical Trial Update: TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium [Phase 2]

View source ↗

Summary

Phase 2 trial of TOCOSOL Paclitaxel for metastatic or locally advanced unresectable transitional cell carcinoma of the urothelium has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Ureteral Cancer
• Urethral Cancer
• Urothelial Carcinoma

Drugs mentioned

• TOCOSOL Paclitaxel (paclitaxel)

Snippet

Sponsor: Achieve Life Sciences | Conditions: Bladder Neoplasms, Ureteral Neoplasms | Phase 2 | Status: COMPLETED